| __timestamp | Catalent, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 6620800000 |
| Thursday, January 1, 2015 | 337300000 | 6533000000 |
| Friday, January 1, 2016 | 358100000 | 6452000000 |
| Sunday, January 1, 2017 | 402600000 | 6588100000 |
| Monday, January 1, 2018 | 462600000 | 5975100000 |
| Tuesday, January 1, 2019 | 512000000 | 6213800000 |
| Wednesday, January 1, 2020 | 577900000 | 6121200000 |
| Friday, January 1, 2021 | 687000000 | 6431600000 |
| Saturday, January 1, 2022 | 844000000 | 6440400000 |
| Sunday, January 1, 2023 | 831000000 | 6941200000 |
| Monday, January 1, 2024 | 935000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Eli Lilly and Company versus Catalent, Inc. from 2014 to 2023. Over this period, Eli Lilly consistently outspent Catalent, with its SG&A expenses peaking at approximately $6.94 billion in 2023, marking a 5% increase from 2022. In contrast, Catalent's expenses showed a more dramatic rise, nearly tripling from $334 million in 2014 to $935 million in 2024. This growth reflects Catalent's aggressive expansion strategy. Notably, Eli Lilly's expenses remained relatively stable, indicating a mature market position. The data for 2024 is incomplete for Eli Lilly, suggesting a need for further analysis. This financial snapshot offers valuable insights into the strategic priorities of these pharmaceutical giants.
Eli Lilly and Company and Novo Nordisk A/S: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Bristol-Myers Squibb Company or Catalent, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Catalent, Inc. or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Catalent, Inc. or Perrigo Company plc
Who Optimizes SG&A Costs Better? Catalent, Inc. or Dynavax Technologies Corporation